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Abstract 
Parkinson’s disease (PD) is characterized by degeneration of dopaminergic neurons in the 
substantia nigra leading to slowness and stiffness of limb movement with rest tremor. Using 
ubiquitin proteasome system inhibitors, rodent models have shown nigrostriatal degeneration and 
motor impairment. We translated this model to the Göttingen minipig by administering lactacystin 
into the medial forebrain bundle (MFB). Minipigs underwent positron emission tomography (PET) 
imaging with (+)-α-[11C]dihydrotetrabenazine ([11C]DTBZ), a marker of vesicular monoamine 
transporter 2 availability, at baseline and three weeks after the unilateral administration of 100 µg 
lactacystin into the MFB. Compared to their baseline values, minipigs injected with lactacystin 
showed on average a 36% decrease in ipsilateral striatal binding potential corresponding to 
impaired presynaptic dopamine terminals. Behaviorally, minipigs displayed asymmetrical motor 
disability with spontaneous rotations in one of the animals. Immunoreactivity for tyrosine 
hydroxylase (TH) and HLA-DR-positive microglia confirmed asymmetrical reduction in nigral TH-
positive neurons with an inflammatory response in the lactacystin-injected minipigs. In conclusion, 
direct injection of lactacystin into the MFB of minipigs provides a model of PD with reduced 
dopamine neurotransmission, TH-positive neuron reduction, microglial activation and behavioural 
deficits. This large animal model could be useful in studies of symptomatic and neuroprotective 
therapies with translatability to human PD. 
 
Keywords: 
Parkinson’s disease, Proteasome inhibition, Lactacystin, PET imaging, Minipig, Vesicular 
monoamine transporter 2, Microglia 
 
Abbreviations: 
[11C]DTBZ = (+)-α-[11C]dihydrotetrabenazine; α-syn = Alpha-synuclein; BPND = non-displaceable 
binding potential; DVR = Distribution volume ratio; Lac = Lactacystin; MFB = Medial forebrain 
bundle; MHC = Major histocompatibility complex; MPTP = 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; MRI = magnetic resonance image; PD = Parkinson’s disease; PET = Positron 
emission tomography; SN = Substantia nigra; SNc = Substantia nigra pars compacta; SNr = 
Substantia nigra pars reticulata; TH = Tyrosine hydroxylase; UPS = Ubiquitin proteasome system; 
VMAT2 = Vesicular monoamine transporter 2; VTA = Ventral tegmental area.
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Introduction	
The ubiquitin proteasome system (UPS) is, together with the autophagy-lysosomal pathway, 
responsible for clearance of damaged intracellular proteins (Cuervo et al., 2004; Ebrahimi-Fakhari et 
al., 2011). Dysfunction of the UPS disturbs protein homeostasis which can lead to accumulation and 
aggregation of unwanted proteins as has been observed in Parkinson’s disease (PD) where Lewy 
body inclusions and neurites containing aggregated alpha-synuclein (α-syn) are characteristically 
present (Betarbet et al., 2005; McNaught and Jenner, 2001). Lewy body inclusions in surviving 
neurons contain poly-ubiquitinated proteins further suggesting impairments of the UPS in PD 
(Iwatsubo et al., 1996; Lowe et al., 1988). 
 
Mutations in genes such as parkin encoding UPS enzymes are associated with familial PD while 
knock-out of the 26S proteasome in mouse models leads to neurodegeneration and Lewy-like 
inclusion body formation (Bedford et al., 2008; Dekker et al., 2003; Kitada et al., 1998; Leroy et al., 
1998). The 26S proteasome consists of a 20S proteolytic core particle and two regulatory 19S 
ATPase subunits that form a lid complex. Poly-ubiquitin tagged proteins are recognized by the 
proteasome leading to selective proteolysis in an ATP-dependent manner. Protein degradation can 
also occur ubiquitin- and ATP-independently in the 26S/20S proteasome, i.e. as described for α-syn 
(Rott et al., 2011; Tofaris et al., 2001; Voges et al., 1999).  
 
Rodent models of PD have been generated using inhibitors of the UPS - a detailed review of these 
models can be found in Bentea et al. (2017). One such inhibitor is lactacystin, which spontaneously 
undergoes hydrolysis to the more potent inhibitor clasto-lactacystin-β-lactone (Dick et al., 1996). 
Clasto-lactacystin-β-lactone can then enter cells, bind covalently to the 20S proteasome and 
irreversibly inhibit its proteolytic sites affecting both the 20S and 26S degradation routes (Dick et al., 
1997). Advantages of lactacystin inhibition models are that they reproduce core pathogenic 
pathways in PD including dopamine cell loss and protein accumulation and aggregation associated 
with motor impairments (McNaught et al., 2002; Niu et al., 2009; Pienaar et al., 2015). Controversy 
still exists about the UPS-inhibition models, as some laboratories have failed to produce an animal 
model of PD after systemic administrations of various inhibitors (Kordower et al., 2006; Mathur et 
al., 2007) although others have succeeded (McNaught et al., 2004; Schapira et al., 2006).  
 
In contrast, models using direct delivery of UPS inhibitors to either substantia nigra (SN) or the 
medial forebrain bundle (MFB) have produced more promising and consistent PD-like syndromes 
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(Konieczny et al., 2014; Li et al., 2008; Lorenc-Koci et al., 2011; Xie et al., 2010). Intranigral injection 
of lactacystin has been shown to produce dopaminergic dysfunction evidenced by both reduced 
midbrain tyrosine hydroxylase (TH) staining and striatal (+)-α-[11C]dihydrotetrabenazine 
([11C]DTBZ) uptake on PET imaging (Harrison et al., 2016; Mackey et al., 2013). Radiolabeled 
DTBZ binds with nanomolar-affinity to the vesicular monoamine transporter 2 (VMAT2) of 
synaptic vesicles in monoaminergic neurons (Scherman et al., 1988) and can non-invasively track 
levels of presynaptic dopamine terminals in the striatum (Koeppe et al., 1996). PET imaging using 
radiolabeled DTBZ has shown VMAT2 reduction in striatum correlating with disease severity of PD 
patients (Hsiao et al., 2014) and SN cell counts in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP)-treated primates (Brown et al., 2013). Furthermore, [11C]DTBZ PET has previously shown 
loss of dopamine neuron integrity in rodent models after 6-hydroxydopamine lesion, UPS 
inhibition and adeno-associated virus vector induced α-syn overexpression (Mackey et al., 2013; 
Phan et al., 2017; Strome et al., 2006). 
 
We wished to extend these findings to a large animal model, more suitable for behavioural 
observations and PET imaging.  Here, we use a combination of behavioural tests, neuroimaging 
with [11C]DTBZ and histological examination to assess the effect of inhibiting the UPS with 
lactacystin in the Göttingen minipig, by unilaterally administering a dose of lactacystin in the MFB 
of the nigrostriatal pathway. 	 	 		
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Material	and	methods	
Animals	
The Danish Animal Experiments Inspectorate (2016-15-0201-01138) approved this study and all 
procedures involving animals were conducted in compliance with the ARRIVE guidelines and the 
2010/63/EU directive for animal experiments. Four female Göttingen minipigs from Ellegaard 
Minipigs ApS (Dalmose, Denmark) aged 10.8 ± 0.4 months with an average weight of 21.0 ± 1.2 kg 
were housed two in each cage at the Aarhus University farm. They were fed a restricted diet with 
free access to tap water. Humidity and temperature were kept at 50-55% and 20°C. Animals 
acclimatized for two weeks prior to the study. On the study days, they were fasted with free access to 
water.  
 
Surgery	
Animals were pre-medicated with 0.8 mg/kg midazolam and 6 mg/kg azaperone IM. Ear veins were 
catheterized (21G venflon) and anaesthesia was induced with approximately 2.5 mg/kg propofol IV. 
Shortly afterwards, the minipigs were intubated (6.0 mm) and anaesthesia was maintained at 
approximately 2.1% isoflurane through a mechanical ventilation setup with 3000 mL/min mix of 0.5 
part 02 and 1 part medical air. Temperature, pulse, oxygen saturation and reflexes were monitored, 
and animals were kept hydrated with a saline drip and warm with an electric blanket during surgery 
(Alstrup, 2010).  
 
Prior to fixation in a magnetic resonance image (MRI)-compatible localizer box (Bjarkam et al., 
2009), 1.25 mg/kg of 0.5% bupivacaine hydrochloride (Marcain®, AstraZeneca, DK) was injected 
subcutaneously over the frontal and zygoma bones at the sites of the surgical incision and at the 
fixation pin holes. As a reference point, a copper-sulfate filled fiducial marker was placed in a drill 
hole in the skull close to bregma (Glud et al., 2017). Animals then underwent a 3D T1-weighted 
MRI brain scan (1.5-T Achieva dStream, Philips) at the MR Research Centre at Aarhus University 
Hospital with 1x1x1 mm voxels, TE 3.7 ms, TR 2200 ms, TI 960 ms, FA 9 deg, 256 x 256. During the 
10 min MRI acquisition, animals were kept anaesthetized with propofol, and hand ventilated. 
 
Based on the reconstructed 1x1x1 mm image, medio-lateral, anterior-posterior and ventral-dorsal 
coordinates were calculated relative to the fiducial marker. Coordinates were calculated for three 
injection sites 1 mm apart (anterior-posterior) in the MFB (Figure 1). A stereotaxic frame was 
attached to the localizer box, the skull was opened and an incision was made in the dura (Glud et al., 
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2011) to permit descent of the cannula to the predetermined coordinates. A total of 100 µg 
lactacystin (CAS# 1258004-00-0, Calbiochem) dissolved in 75 µL saline (n = 3, pig#2,3,4) or saline 
alone (n = 1, pig#1) was injected unilaterally using a 50 µL 705 RN Hamilton Syringe (VWR) along 
three anterior-posterior sites (25 µL each) in the nigrostriatal pathway. Infusion rate was 5 µL/min 
over 4 minutes and at one-minute intervals the needle was retracted 1 mm to allow diffusion of the 
solution. The needle was left in place for an additional 3 minutes before withdrawal and the skin 
was sutured. Postoperatively, the animals received antibiotics and analgesics including 0.03 mg/kg 
buprenorphine IM (Temgesic®, Indivior UK Limited) three times a day and 1.5 mg/kg meloxicam 
(Metacam®, Boehringer Ingelheim, DK) and 30,000 IE/kg benzylpenicillin procain (Penovet®, 
Boehringer Ingelheim, DK) once a day for 3 days. 
 
Behavioural	analysis	
Behavioural ratings were performed at baseline and every week post-surgery in a 13 m2 arena for 10 
min. Videos were acquired at every performance and were reassessed for each individual pig by 
comparing with the baseline recordings to reduce subjective bias. Neurological scoring of the 
animals was based on Mikkelsen et al. (1999) and included (A) Motility - 0: normal, 1: slightly 
compromised, 2: moderately compromised, 3: moderately compromised (freezing behaviour), 4: 
severely compromised, (B) Position abnormality/Coordination - 0: normal, 1: abnormal leg 
positioning (i.e. crossing of hindlimbs), 2: balance compensation, 3: clear coordination issues, and 
(C) Feeding function - 0: normal, 1: compromised, 2: rigid jaws (total maximum score = 9). In 
addition to the feeding function, we measured a feeding duration obtained by timing the animals as 
they ate 1.5 dL of food pellets, from snout in until empty.  
 
[11C]DTBZ	PET		
One week pre-surgery and 3 weeks post-surgery animals had a [11C]DTBZ PET scan. As previously 
described (Landau et al., 2017), minipigs received a mixture of 1.2 mg/kg midazolam and 6.0 mg/kg 
S-ketamine IM prior to inserting an ear vein catheter through which induction of anaesthesia was 
administered (mixture of 1.2 mg/kg midazolam and 3.0 mg/kg S-ketamine). Animals were then 
intubated and mechanically ventilated 3000 mL/min with an O2 and medical air ratio of 1:2.2 and 
anaesthesia was maintained with 2.1% isoflurane. Anaesthetic levels, temperature and vital 
functions were monitored regularly throughout the scan (Alstrup, 2010).  
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Minipigs were placed in a Biograph 64 TruePoint  PET/CT scanner (6.7.2, Siemens) with the brain 
at the centre of the field of view. A transmission CT scan was obtained for attenuation correction. 
The average injected dose, mass and specific activity at the time of injection of [11C]DTBZ were 
385.7 ± 19.9 GBq, 2.1 ± 2.0 µg and 64.8 ± 39.7 GBq/µmol, respectively. No statistically significant 
differences in these were observed between the baseline and the post-surgery scan values. 
[11C]DTBZ was dissolved in 20 mL saline and injected intravenously over 30 s followed by a 20 mL 
saline flush (Alstrup et al., 2017, in press). PET was acquired for 90 min in list mode. Images were 
reconstructed using TrueX with a point-spread function (3 iterations and 21 subsets) and smoothed 
with a 2 mm Gaussian kernel. PET data were rebinned as: 5x1, 3x5, 4x10 and 2x15 min time frames.  
 
Data	analysis	
For quantitative analysis, reconstructed images were processed in PMOD v. 3.610 (PMOD 
Technologies, Zürich, Switzerland). Images were rigidly co-registered to a minipig average MRI 
with standard volumes of interest (Watanabe et al., 2001). Time-activity curves were obtained from 
right and left striatum and the cerebellum. Using the Logan graphical approach (Logan et al., 1996), 
the slope of data from 20-90 minutes was used to calculate the distribution volume ratio (DVR) in a 
target region of interest relative to the cerebellum (as a low dopamine terminal-containing 
reference). The average tissue-to-plasma rate constant from the reference region ( k2’ ) did not differ 
between the animals and a fixed value (0.15 min-1) was used for all. Data are presented as the non-
displaceable binding potential (BPND = DVR - 1) using Graphpad Prism v7.0. Parametric maps of 
Logan reference BPND were calculated from the co-registered PET images in the PXMOD toolbox. 
  
Histology	analysis	
One month post-surgery, minipigs were deeply anaesthetized with a mixture of 2.5 mg/kg 
midazolam and 20 mg/kg azaperone and were euthanized with an overdose of 20 mL 400 mg/mL 
pentobarbital sodium (Exagon®Vet, Richter Pharma, Austria) transcutaneous to the heart before 
transcardial perfusion with 5 L of 4% paraformaldehyde was performed (Ettrup et al., 2011). The 
fixed brain was removed for histological analysis as described in Bjarkam et al. (2017). Brains were 
stored in 4% formaldehyde at 4°C until they were pre-cut into 1 cm thick coronal blocks and 
cryoprotected in 30% sucrose and 0.15 M Sørensen’s phosphate buffer for one week. Brain slabs 
were frozen in isopentane cooled to -40°C for 1 min before being cut into coronal sections (40 µm) 
on a CryoStar NX70 (Thermo Scientific). Every brain slab covering striatum, thalamus, SN and 
locus coeruleus was cut in 10 series (slices in each series were spaced 400 µm) and were stored free-
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floating in DeOlmos at -20°C. One set was mounted directly on 0.5% gelatin-coated glass and 
stained with Nissl. In brief, mounted sections were stained with 0.1% toluidine blue in citrate buffer 
(pH 4.0) at room temperature for 9 min, rinsed shortly in distilled water, dehydrated 2 x 30 sec in 
99% alcohol, cleared with xylene and cover slipped with Eukitt®. 
 
On day 1 of the immunohistochemistry staining, free-floating sections were initially washed in tris-
buffered saline containing 1% Triton X-100 (TBS-T, 0.05 M, pH 7.4) for 3 x 5 min. Target retrieval 
was conducted for all antibodies, except anti-α-syn, in a water bath at 80°C with Dako retrieval 
buffer (S1699) for 30 min followed by cooling to room temperature for 30 min. Retrieval buffer was 
washed off with 2 x 5 min TBS-T and TBS was added for 5 min prior to quenching the endogenous 
peroxidase with 3% H2O2 in 0.05 M TBS for 15 minutes. Sections were again rinsed in TBS for 10 
min followed by 2 x 10 min in TBS-T. Then, sections were incubated with 0.2% skim milk powder 
in TBS-T for 30 minutes. Finally, rabbit anti-TH (1:500, #AB152, Lot: 2893306, EDM Millipore 
Corp.), mouse anti-HLA-DR (1:100, #M0746, Lot: 20020039, Dako), or mouse anti-α-syn (1:5000, 
Syn211, #MA1-12874, Lot: QF2033452, Thermo Scientific) in the 0.2% milk solution was added as 
primary antibody to the slides and incubated overnight at 4°C. Primary antibody was omitted for a 
few sections for every procedure, which served as negative controls.  
 
On day 2, sections were rinsed in 3 x 10 min TBS-T followed by incubation for 2 hours with the 
appropriate horseradish peroxidase (HRP) labeled secondary antibody (anti-TH, 1:400, HRP-
labeled anti-rabbit, #P0448, Lot: 20017525 Dako or anti-HLA-DR, 1:400, HRP-labeled anti-mouse, 
#P0447, Lot: 20019698, Dako) or 1 hour with biotinylated secondary antibody (anti-α-syn 211, 
1:200, biotinylated anti-mouse, #A90-116B, Lot: A90-116B-10, Bethyl) in TBS-T. Sections were 
rinsed again 3 times in TBS-T for 10 min. For the biotin-labeled secondary antibody (anti-α-syn), 
an avidin-biotin-peroxidase complex solution (Vectastain® elite® ABC-kit, #VECTPK-6100, Vector 
Laboratories) was added for 1 hour prior to a final 10 min 2 x TBS-T and 1 x TBS rinse. The bound 
HRP or avidin-biotin complex were visualized with a mix of 0.1% 3,3’-diaminobenzidine (DAB; 
DAB-Safe, Saveen Werner AB) in TBS and 0.03% H2O2. After 5 min, the reaction was terminated by 
a 3 x 1 min in TBS. Sections were then mounted on 0.5% gelatin-coated glass slides, dehydrated in 2 
x 5 min 99% ethanol and cleared in xylene for 5 min before being coverslipped using Eukitt®. Brain 
sections were photographed using a Leica camera (DFC 480) connected to a Leica microscope 
(DM5000B).  
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Analysis	of	TH	immunoreactivity	in	SN	and	VTA	
TH immunohistochemistry staining was semi-quantified by selecting matched sections of the SN 
and VTA of each minipig and measuring the area covered by DAB product presented in µm2. Please 
note that we did not measure the DAB staining intensity, because DAB does not meet the Lambert-
Beer criteria for photometric material, as there is no linear association between staining intensity 
and DAB concentration. First, a series of 24 bit colour photographs was taken with the Leica camera 
and microscope using similar exposition time, levels and white balance (2560 x 1920 pixels). Then, 
the pictures were merged in Photoshop (Adobe, version 16.0.0, 2015), to obtain a final coronal 
section of the brain. To allow measurements, photographed sections were converted into 8 bit 
images followed by semi-automatic segmentation (threshold) using intensity channel from HSI 
images, which gives the highest contrast between background and stained tissue. After the initial 
automatic setting, the threshold was manually corrected to ensure that all TH-positive stains were 
covered within SN and VTA. The area (µm2) was estimated in ImageJ (Schneider et al., 2012) and 
averaged per hemisphere/brain for each minipig. As SN and the VTA are difficult to distinguish, the 
regions were carefully delineated.   
 
Results	
Behaviour	
The minipig injected unilaterally with saline (pig #1) displayed no feeding or behavioural changes in 
the neurological scoring test compared to its own baseline scores (Figure 2a & b). Pig#2 unilaterally 
injected with lactacystin displayed clear coordination issues, which were most predominant in the 
contralateral hind-limb post-surgery. Small steps, rigidity and midline positioning of both hind 
limbs characterized its gait, the latter a consequence of the ipsilateral hind limb compensating for 
the contralateral leg rigidity. Its motility was moderately compromised with freezing behaviour 
especially in the first 3 weeks following the unilateral lactacystin injection (Figure 2a). Pig#2 also 
displayed the most pronounced change in eating behaviour, with slow eating speed and rigid jaws 
(Figure 2b). Pig#3 had mildly impaired mobility over the 4 weeks compared to its baseline 
assessment with an increased eating duration the first week (Figure 2a & b). Pig#4 displayed 
substantial spontaneous rotational behaviour and freezing following the unilateral lactacystin 
injection, which was still present 4 weeks after injection. The animal rotated towards the 
contralateral injection site in small circles with the hind limbs placed in the centre only moving 
slightly, while the front limbs moved on the perimeter of the circle. It showed only small changes in 
eating behaviour and mobility compared to its baseline status (Figure 2a & b). 
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[11C]DTBZ	PET	results	
We imaged dopaminergic terminal function in vivo with [11C]DTBZ PET, a marker of VMAT2 
availability in the minipig brain at baseline and following unilateral injection of saline or lactacystin 
in the nigrostriatal pathway. Binding of the tracer to the contralateral and ipsilateral striatum at 
baseline was similar and consistent between the 4 animals. Quantification of [11C]DTBZ BPND 
revealed an average of -36 ± 8% % !"#$!"#$%&'$ − 1  reduction in binding to the VMAT2 in the 
ipsilateral striatum across all 3 lactacystin-injected minipigs while the saline-injected minipig 
showed only a small decline (-10%) in binding at three weeks compared to their own ipsilateral 
striatum baseline values (Figure 3a). In the post intervention scan, the VMAT2 binding to the 
contralateral striatum was unchanged for the saline-injected pig#1 and the lactacystin-injected 
pig#2 compared to their own baseline. In contrast, a decreased binding of -25 ± 3% was observed in 
the contralateral striatum for pigs #3 and #4 compared to their own baseline binding. 
 
By comparing the %ipsilateral vs. contralateral change of each minipig % !"#!$%&'(%$!"#$%&'&$(%&' , we 
observed no change in binding at baseline or after three weeks for the saline-injected pig#1. 
Asymmetric binding was however observed for all 3 lactacystin-injected minipigs with ipsilateral 
binding being lowered to an average of 76 ± 14 % of contralateral binding at the three week post-
injection PET scan (Figure 3b).  
 
In figure 3c, PET images are presented as BPND voxel-wise maps and asymmetric binding in 
striatum of the three lactacystin-injected minipigs can be seen. Moreover, it should be noted that 
the average binding in both the contralateral and ipsilateral striatum of the lactacystin-injected 
minipigs appear lower than both the binding seen in the baseline and saline scans. 
 
Histology		
The Nissl stained brain sections and TH stains of the fiber tract confirm that the MFB in the 
nigrostriatal pathway was correctly targeted. Targeting was similar for all minipigs anterior to the 
SN and ventral to thalamus, though in pig#3 the injection seemed to be located slightly dorsal to the 
MFB. The Nissl stains of SN pars compacta (SNc) showed that fewer neurons were visualized in the 
ipsilateral side compared to the contralateral side in the lactacystin-injected animals, especially in 
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pig#2 and #4 (Figure 4b). In the saline-injected pig#1, SNc of both hemispheres appeared identical 
(Figure 4b). 
 
Brain sections covering the SN from all 4 animals were stained with antibodies specific for the TH 
enzyme localized in the cytosol of dopaminergic neurons (Figure 5a). The three lactacystin-injected 
minipigs had asymmetrical changes in the SN, which was in contrast to the saline-injected pig#1 
that displayed symmetrical anti-TH staining in the SN. We semi-quantified this difference by 
measuring the nigral TH-immunopositive area in both sides of all minipigs and an average 
reduction of -62% ± 25% for the lactacystin-injected pigs was found in the ipsilateral side compared 
to the contralateral side while a 10% increase was found in the saline-injected minipig (Figure 5b). 
In contrast, the area of TH-immunoreactivity in the ventral tegmental area (VTA) close to the 
midline on the ipsilateral side was not affected by lactacystin administration and no differences were 
found between the ipsilateral and contralateral side in any of the animals or between the saline- and 
lactacystin-injected minipigs (Figure 5b). 
 
Similar staining patterns were observed in the striatum, suggesting a loss of TH positive projections 
to the ipsilateral striatum in the animals injected with lactacystin (Figure 5c). No differences 
between the two hemispheres were observed in striatum of the saline-injected minipig. Brain 
sections covering locus coeruleus were also investigated for TH-immunoreactivity, however, 
homogenous expression was observed in both hemispheres of all minipigs. 	
Lactacystin injection in the nigrostriatal pathway caused an inflammatory response, which 
manifested as increased HLA-DR expression by activated microglia in the SN, VTA and other areas 
adjacent to the needle of the lactacystin-injected minipigs (Figure 6). For all 4 injected minipigs, 
including the saline-injected minipig, local microglial activation was observed close to the needle 
tract progressing dorsally from the cortex and ventrally through the central telencephalic white 
matter tract and thalamus reaching the MFB. Furthermore, microglial activation was also seen in 
the ipsilateral striatum (predominantly the internal capsule), thalamus and in the SN away from the 
injection site in the lactacystin-injected minipigs. Most microglia observed in the different brain 
regions were hypertrophic and in the ipsilateral SN of the lactacystin-injected animals, some were 
amoeboid with enlarged cell bodies and thick processes characteristic of highly activated microglia 
(Figure 6). Only a few microglia were observed in the saline-injected minipig on the ipsilateral side, 
at a distance from the injection site (striatum, SN and VTA), and most had a resting morphology. 
However, some light hypertrophic microglia were observed locally in the ipsilateral VTA. Similarly, 
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only lightly scattered microglia with a ramified morphology, and a few with hypertrophy, were 
observed contralateral to the injection site in all minipigs (Figure 6). 
 
In addition to the TH and HLA-DR stains, we also examined adjacent slices in all animals for 
possible α-syn aggregates in the SN and VTA. In the SNc, mostly fibers stained for α-syn were 
visible in all the minipigs, although α-syn-immunopositive intracytoplasmatic granular staining 
could be observed in some neurons in the ipsilateral side of the lactacystin-injected minipigs (Figure 
7). In SN pars reticulata (SNr), a punctate and granular staining of α-syn was observed in all pigs, 
though it appeared slightly denser with larger granules in the lactacystin-injected minipigs 
compared to the saline-injected minipig (Figure 7). No differences were observed between the 
ipsilateral and contralateral side in any of the animals. 
 
The neurons located in the ipsilateral VTA showed a clear expression of α-syn in the soma (Figure 
7). This was in contrast to the site contralateral to the injection, where only puncta, presumably 
synapses, were visible in the VTA. Interestingly, the accumulated α-syn in neurons was not only 
seen in all 3 lactacystin-injected minipigs, but also in the ipsilateral side of the saline-injected 
minipig (Figure 7). This indicated that the needle insertion, including transient rupture of the 
blood-brain barrier, and the tension caused by the volume of fluid injected in the MFB affected α-
syn turnover in primarily VTA located neurons. 
 
Discussion	
This study shows that inhibition of the UPS by unilateral lactacystin injection induces a hemi-
parkinsonian-like phenotype in Göttingen minipigs. This phenotype is associated with behavioural 
slowness and asymmetry, in vivo reductions in striatal [11C]DTBZ binding detected by PET, and TH 
binding asymmetry in striatum and SN, HLA-DR-positive microglia and α-syn positive neurons in 
SN detected by histology. For the first time, we translate the UPS inhibition animal model 
mimicking Parkinson’s disease to the Göttingen minipig.  
 
An advantage of using a large animal model like the Göttingen minipig is that it has a large brain 
with clearly defined gyri, which makes it suited for neuroimaging deep brain structures using 
human scanners at sufficient resolution. Another advantage is the ability to use human clinical 
devices and stimulation parameters for interventions, for example for deep brain stimulation, in 
future studies. As previous studies had found nigral dopamine neuron loss, α-syn accumulation, 
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glial activation and motor deficits following stereotaxic infusion of lactacystin in the MFB of rats 
and mice (Li et al., 2008; Vernon et al., 2011; Xie et al., 2010), we also decided to inject the minipigs 
in the MFB to increase our chances of reaching a maximum number of SN neurons via the 
dopaminergic fibers while avoiding direct harm to the SN neurons.  
 
We observed bradykinesia and rigidity in the contralateral limbs of two minipigs and spontaneous 
contralateral rotations in another minipig following the unilateral injection of lactacystin in the 
nigrostriatal pathway, which lasted throughout the 4 weeks of this study (Figure 2a). Spontaneous 
rotations were only observed in one animal, which might be a result of differential lesion severity 
across the animals. The contralateral hypokinesia and the need to maintain balance may play a part 
in the observed contralateral rotations in one minipig. Also, as has been speculated for both 
lactacystin- and epoxomicin-injected rodents, the spontaneous contralateral rotations might have 
been caused by hyperactivity of the surviving dopaminergic neurons (Bentea et al., 2015; Konieczny 
et al., 2016; Subramaniam et al., 2014). Indeed, other studies have shown unpredictable rotation 
behaviour in unilaterally-lesioned animals in response to L-dopa due to uncontrolled fluctuations in 
extracellular dopamine varying with lesion degree (Abercrombie et al., 1990; Kaariainen et al., 
2012).  
 
Our finding of decreased [11C]DTBZ BPND in the ipsilateral striatum of lactacystin-injected minipigs 
is consistent with human studies of decreased binding potential in striatum of PD patients 
compared to normal controls (Bohnen et al., 2006) as well as in various animal models in rodents 
and primates (Brown et al., 2013; Mackey et al., 2013; Phan et al., 2017). Specifically, in clinically 
hemi-parkinsonian patients, decreased striatal [11C]DTBZ binding was noted in the striatum 
contralateral to the most affected or symptomatic side (Lee et al., 2000). Even though VMAT2 is 
present in both noradrenergic, serotonergic and dopaminergic neurons, the striatal content of 
dopaminergic neurons represents ~90% of [11C]DTBZ binding. Another human study by Hsiao et 
al. (2014) detected a decreased binding in PD patients using [18F]DTBZ PET both in striatum and 
SN correlating with disease stage. While clear decreased VMAT2 binding was detected in the 
striatum in our study, we were unable to accurately localize and detect any changes of the minipig 
SN using [11C]DTBZ PET due to the size of the SN/VTA area and partial volume effects associated 
with poor scanner resolution. However, a good correlation was found between [11C]DTBZ striatal 
binding and nigral cell counts in MPTP-treated non-human primates (Brown et al., 2013). 
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A small decline in [11C]DTBZ binding was noted in the ipsilateral striatum (10%) of the saline 
treated minipig three weeks after injection compared to its baseline value but its % 
ipsilateral/contralateral ratio remained at ~100% post-surgery. Furthermore, no visual differences 
were detected in its immunohistochemistry in either the SN or the striatum thus this small 
difference may be accounted for by a number of factors such as test-retest reproducibility and 
positioning of the animal. Lactacystin-injected pigs #2, #3 and #4 had similar reduced ipsilateral 
striatal [11C]DTBZ BPND binding (~36%) compared to baseline. When assessing nigral TH levels by 
immunohistochemistry, we observed a larger reduction in pigs #2 and #4 (73 and 90%, respectively) 
in the ipsilateral vs. contralateral SN, whereas pig #3 showed a lesser decline of 31%. Small 
deviations in placement of the needle may have contributed to the differing severity of lesion and 
symptoms between animals. The lactacystin injection seemed to be located slightly above the MFB 
in pig#3 on the histological sections, and indeed, pig#3 presented with fewer motor symptoms and 
larger ipsilateral TH positive area than pig#2 and #4. Naturally, small inter-individual effects may 
influence the site of injection, as the stereotaxic coordinates are calculated from a MR resolution of 
1x1x1 mm and the needle may bend slightly during the penetration of 3-4 cm brain tissue from the 
cortical surface to the MFB target. Furthermore, the precision of the stereotactic frame may 
introduce minor errors. 
 
The average percentage ipsilateral to contralateral reduction in the [11C]DTBZ BPND was not as large 
as the ipsilateral side change at baseline vs. three weeks after lactacystin-injection (Figure 3b) due to 
the contralateral decreased binding in striatum present in pig#3 and #4. This suggests that the 
contralateral side was also affected by the lactacystin injection three weeks after the surgery 
presumably due to hemisphere interconnections or passive diffusion. VMAT2 is believed to be a 
stable terminal density marker and to not undergo major compensatory regulatory changes (Suzuki 
et al., 2001; Vander Borght et al., 1995), however, this assumption has been challenged (Kilbourn et 
al., 2010; Tong et al., 2008). Decreased VMAT2 binding could, therefore, be due to increased 
vesicular dopamine levels, presynaptic dopamine terminal impairment or cell death of the SN 
neurons. The histology images (Figure 5) show a visible loss of TH-positive neurons in the 
ipsilateral SN and of TH-positive fibers in the striatum of the lactacystin-injected minipigs, which 
reflect either down-regulation of the TH enzyme or actual cell loss. Most likely, the observed 
ipsilateral VMAT2 and TH reductions are a mix of both scenarios (cell loss and enzyme/transporter 
reduction), and the Nissl stains (Figure 4b) as well as the motor symptoms support that cell loss 
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occurred. Intact TH-stains of the contralateral SN and striatum was observed in all 3 lactacystin-
injected minipigs. 
 
It has to be noted that a direct comparison between TH staining and [11C]DTBZ imaging cannot be 
done, as the [11C]DTBZ PET imaging was done 3 weeks after injection while the animals were 
euthanized 4 weeks after injection providing tissue for the histology. However, we can conclude that 
already after 3 weeks, synaptic disruption was seen in the asymmetrical in vivo striatal [11C]DTBZ 
binding, which was still present 4 weeks after injection visualized by TH staining. 
 
Post-mortem human studies and animal experiments have found glial-mediated 
neuroinflammation to be associated with PD pathogenesis, in addition to α-syn pathology (Hirsch 
and Hunot, 2009; McGeer and McGeer, 2008). In our model, we observed ipsilateral HLA-DR-
positive microglia in the SN and VTA of the three lactacystin-injected minipigs (Figure 6). HLA-DR 
is an antigen presenting major histocompatibility complex (MHC) class II receptor that is 
upregulated when microglia are activated. The inflammatory response in the saline-injected minipig 
was localized close to the needle tract, and as only few light hypertrophic microglia were observed in 
the ipsilateral VTA, it is likely that it was solely due to the minor cell damage caused by the needle 
and fluid injection. 
 
On the contrary, lactacystin induced scattered microglia activation in the SN and VTA ipsilaterally, 
while only few HLA-DR positive glial cells were observed contralaterally. Microglial activation 
following lactacystin administration has previously been observed in the SN of rodents and may 
reflect pro- or anti-inflammatory effects leading to protection against or increased neuronal 
degeneration depending on multiple factors such as doses, proximity and timing (Pienaar et al., 
2015; Xie et al., 2010). We followed the minipigs for only 4 weeks so it is uncertain if the activation 
would have sustained for a longer time. Interestingly, monkeys injected with MPTP showed 
dopaminergic neurodegeneration and persistent microglial activation several years after 
intoxication further suggesting microglial activation is involved in the neurodegeneration-process 
(McGeer et al., 2003). 
 
Based on the TH-immunoreactivity, the dopamine neurons in the VTA were not affected by the 
lactacystin-injection (Figure 5). This insensitivity of the VTA to lactacystin has previously been 
observed in other animal models (Bentea et al., 2015; Mackey et al., 2013). This is consistent with a 
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study in mice infused directly in the VTA with a proteasome inhibitor, which showed no functional 
changes in VTA dopaminergic neurons while the nigral neurons were harmed (Subramaniam et al., 
2014). Interestingly, we observed that α-syn accumulated in the ipsilateral VTA neurons and to a 
lesser extent in the SNc neurons in both lactacystin- and saline-injected minipigs, while synapses 
were stained more widespread in both sides (Figure 7). This indicated that the needle penetration 
and volume of fluid itself affected either the degradation system or may have led to increased 
expression of α-syn in the VTA located neurons. Hence it is a non-specific effect unrelated to 
lactacystin. Light hypertrophic microglia were observed in the ipsilateral VTA of both the saline- 
and lactacystin-injected minipigs, which were not present contralaterally. Thus, it can be speculated 
that the minor inflammatory response occurring in VTA could trigger α-syn accumulation, as 
MHC class II expression assessed by HLA-DR has been shown to significantly correlate with 
deposition of α-syn in SN of human PD patients (Croisier et al., 2005).  
 
Previous reports have shown an increased ipsilateral SNr α-syn immunoreactivity to lactacystin-
treatment in both mice and rats compared to control animals accompanied by neuroinflammation 
and oxidative stress (Miwa et al., 2005; Savolainen et al., 2017). We observed immunopositive α-syn 
granules in both the ipsilateral and contralateral SNr that were slightly more pronounced in the 
lactacystin- than the saline-injected animals (Figure 7), presumably caused by the minor 
inflammatory response seen in these animals. 
 
The main limitations of this study are the lack of quantitative stereology and small sample sizes as 
only three animals were injected with lactacystin and only one with saline as a control. However, all 
three lactacystin animals showed consistent behavioural, neuropathological and neurotransmission 
effects, so we conclude that lactacystin has similar effects in minipigs as it has in rodents. Moreover, 
although we only had one saline control animal, we have used the [11C]DTBZ tracer in a number of 
other studies in Göttingen minipig and the binding values of our saline treated animal at both time-
points are consistent with the findings in untreated animals in our previous work (Lillethorup et al., 
unpublished results). Furthermore, by acquiring baseline behaviour and PET data and injecting 
unilaterally, the animals became their own internal controls for the longitudinal assessment. 
 
Similar UPS inhibition models in rodents have reported non-specific damage of lactacystin to non-
dopaminergic and GABAergic neurons in the nigra (Konieczny et al., 2015) as well as to other 
neighbouring systems such as pedunculo-pontine nucleus (Pienaar et al., 2015) and an additional 
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limitation of our study is that other transmitter systems were not investigated here. As lactacystin is 
an irreversible inhibitor, it would also be interesting to test its effect over a longer time period than 
the 4 weeks in this study, in a longitudinal design to investigate if the impairments are sustained or 
lead to even further progression or recovery. However, a recent study suggests that lactacystin 
induces a stable lesion in rodents during an 8 week period (Mejias et al., 2016) and thus our timeline 
was likely sufficient for a preliminary study. 
 
Conclusions		
This non-primate large animal injected with lactacystin directly into the nigrostriatal pathway may 
provide a promising model of PD. Its use is supported by the associated motor impairments, 
lowered VMAT2 binding in striatum measured by [11C]DTBZ PET, reduced area of TH-positive 
neurons in SNc and microglial activation. 
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Figure	Legends	
 
Figure 1. MRI-based stereotaxic injection in the MFB of the minipig. Left: Coronal MRI overlaid with needle 
visualizing the injection of lactacystin in the MFB. Three injections were performed 1 mm apart (anterior-
posterior). Right: Nissl staining of a representative brain slice from pig#4 with visible needle tract (arrow). 		
 
Figure 2. Motor performance and eating duration. (a) Neurological score and (b) Eating duration assessed 
every week.  	
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Figure 3. VMAT2 binding levels determined by in vivo [11C]DTBZ PET. (a) BPND values are presented for each 
minipig at baseline and 3 weeks post-surgery in both the contralateral (left graph) and ipsilateral striatum 
(right graph). (b) The ipsilateral relative to contralateral percentage change are shown of all animals at baseline 
(pig#1-4 = ), following saline injection (pig#1= ) and lactacystin injection (pig#2 = ; pig#3 = ; pig#4 = 
). (c) Parametric BPND maps of in vivo [11C]DTBZ PET are displayed in coronal, transverse and sagittal views. 
The top row represents an average of the 4 BPND PET images obtained at baseline. The middle row display 
images of the saline-injected minipig at its 3-week scan while the bottom row shows the voxel-wise parametric 
maps of an average of the three lactacystin-injected minipigs 3 weeks post-injection. While the baseline and the 
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saline scans show similar binding in ipsilateral and contralateral striatum (top and middle row), a visible 
decreased binding can be observed in the ipsilateral striatum after unilateral lactacystin injection (bottom row). 
 
Figure 4. SN pars compacta (SNc) visualized with Nissl staining to determine cell loss. (a) Left: Saline-injected 
pig#1 is displayed and rectangular boxes are placed to indicate the anatomical location of the magnified inserts 
below. Right: An adapted schematic drawing of the Göttingen minipig brain depicting the section plane 
corresponding to S20 in the histological atlas by Bjarkam et al. (2016) (http://www.cense.dk/minipig_atlas/). 
(b) Magnified images are shown of corresponding ipsilateral and contralateral SNc sections of the saline-
injected pig#1 (top left), lactacystin-injected pig#2 (top right), lactacystin-injected pig#3 (bottom left) and 
lactacystin-injected pig#4 (bottom right). Lac = lactacystin. Scale bars = 100 µm. 
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Figure 5. Representative TH immunohistochemistry sections shown for the SN, VTA and striatum. (a) Upper 
left: saline-injected pig#1. Upper right: lactacystin-injected pig#2. Bottom left: lactacystin-injected pig#3. 
Bottom right: lactacystin-injected pig#4. (b) Measurement of the immunopositive SN and VTA area in 
contralateral and ipsilateral side of each minipig post-surgery. Each point on the graph represents mean and 
standard deviation (error bar) of measurements done on 3 adjacent sections covering the SN and VTA for each 
minipig. (c) Representitative brain section of striatum in lactacystin-injected minipig. The reduced staining of 
TH fibers can be appreciated in the ipsilateral stiatum compared to the contralateral striatum. Needle injection 
tract is visible in the cortex (arrow). Lac = lactacystin. 
 
Figure 6. HLA-DR-positive microglia in SN and VTA of lactacystin-injected minipig #2. Mild hypertrophic and 
phagocytic microglia were seen in the ipsilateral side, while ramified and a few hypertrophic microglia were 
observed contralateral to the injection site. Arrows indicate mildly hypertrophic microglia.  
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Figure 7. α-syn histology in SN pars compacta (SNc), SN pars reticulata (SNr) and ventral tegmental area 
(VTA). To the left, α-syn staining is shown in the saline-injected minipig# 1, and to the right, in a lactacystin 
(Lac)-injected minipig #2. Neurons and synapses (puncta) in the VTA expressing α-synuclein are visible in the 
ipsilateral side in Lac-injected minipig. Only puncta and no neurons were visible in non-injected side in the 
VTA. In the SNc of both saline- and lactacystin-injected pigs, small puncta were visible on both ipsi- and 
contralateral sides with a few neurons stained ipsilaterally in the lactacystin-injected animal. α-positive 
granules were observed in SNr and no differences were seen between the ipsi- and contralateral side in either 
brains. Large rectangular boxes show the magnified SNc images while the small rectangular boxes show the 
magnified VTA and SNr inserts. Arrows mark stained neurons. Scale bars in inserts: 50 µm. 
